ChitogenX Inc. (CHNXF)
USD 0.01
(-29.58%)
USD 0.01
(-29.58%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -2.73 Million CAD | 44.07% |
| 2023 | -4.89 Million CAD | -39.33% |
| 2022 | -3.51 Million CAD | -14.74% |
| 2021 | -3.06 Million CAD | -28.41% |
| 2020 | -2.38 Million CAD | 7.11% |
| 2019 | -2.56 Million CAD | -26.84% |
| 2018 | -2.02 Million CAD | -9.87% |
| 2017 | -1.84 Million CAD | -177.91% |
| 2016 | -662.35 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -391 Thousand CAD | 37.14% |
| 2024 Q1 | -1.47 Million CAD | -22.69% |
| 2024 Q4 | -743 Thousand CAD | -90.03% |
| 2024 FY | -2.83 Million CAD | 42.15% |
| 2024 Q2 | -622 Thousand CAD | 57.86% |
| 2023 Q4 | -1.2 Million CAD | 0.74% |
| 2023 Q1 | -1.27 Million CAD | -36.63% |
| 2023 Q2 | -1.13 Million CAD | 11.08% |
| 2023 FY | -4.89 Million CAD | -39.33% |
| 2023 Q3 | -1.21 Million CAD | -7.16% |
| 2022 Q3 | -1 Million CAD | -71.02% |
| 2022 FY | -3.51 Million CAD | -14.74% |
| 2022 Q4 | -931 Thousand CAD | 7.73% |
| 2022 Q2 | -590 Thousand CAD | 36.97% |
| 2022 Q1 | -936 Thousand CAD | 3.6% |
| 2021 Q3 | -631 Thousand CAD | -48.12% |
| 2021 Q2 | -426 Thousand CAD | 52.24% |
| 2021 Q1 | -892 Thousand CAD | -194.39% |
| 2021 Q4 | -971 Thousand CAD | -53.88% |
| 2021 FY | -3.06 Million CAD | -28.41% |
| 2020 Q2 | -562 Thousand CAD | -2.55% |
| 2020 Q3 | -711 Thousand CAD | -26.51% |
| 2020 Q4 | -303 Thousand CAD | 57.38% |
| 2020 FY | -2.38 Million CAD | 7.11% |
| 2020 Q1 | -548 Thousand CAD | 22.14% |
| 2019 Q3 | -749 Thousand CAD | -268.26% |
| 2019 Q1 | -407 Thousand CAD | 29.3% |
| 2019 Q2 | 445.13 Thousand CAD | 209.37% |
| 2019 Q4 | -703.81 Thousand CAD | 6.03% |
| 2019 FY | -2.56 Million CAD | -26.84% |
| 2018 Q3 | -596.1 Thousand CAD | -71.46% |
| 2018 Q2 | -347.66 Thousand CAD | -49.32% |
| 2018 Q1 | -232.83 Thousand CAD | -43.09% |
| 2018 Q4 | -575.68 Thousand CAD | 3.43% |
| 2018 FY | -2.02 Million CAD | -9.87% |
| 2017 Q2 | -539.05 Thousand CAD | -99.47% |
| 2017 Q4 | -162.71 Thousand CAD | 64.84% |
| 2017 FY | -1.84 Million CAD | -177.91% |
| 2017 Q1 | -270.24 Thousand CAD | 59.25% |
| 2017 Q3 | -462.82 Thousand CAD | 14.14% |
| 2016 FY | -662.35 Thousand CAD | 0.0% |
| 2016 Q1 | -36.53 Thousand CAD | 0.0% |
| 2016 Q2 | -53.58 Thousand CAD | -46.68% |
| 2016 Q3 | -166.68 Thousand CAD | -211.07% |
| 2016 Q4 | -663.12 Thousand CAD | -297.83% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.25 Million USD | -117.834% |
| Skye Bioscience, Inc. | -13.67 Million USD | 79.988% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 103.343% |
| Nascent Biotech, Inc. | -2.22 Million USD | -22.697% |
| Qrons Inc. | -643.67 Thousand USD | -325.058% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 64.828% |
| CSL Limited | 3.7 Billion USD | 100.074% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 84.67% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 45.763% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -298.282% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 95.071% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -558.517% |
| Rebus Holdings, Inc. | -664 Thousand USD | -312.048% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -104.878% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -602.313% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 82.76% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 96.189% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 155.668% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -945.368% |
| SQZ Biotechnologies Company | -75.82 Million USD | 96.392% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 4.017% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -78.119% |
| Mesoblast Limited | -84.14 Million USD | 96.749% |
| Marizyme, Inc. | -34.08 Million USD | 91.973% |
| Genus plc | 6.4 Million USD | 142.75% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 128.083% |
| Pharming Group N.V. | -4.87 Million USD | 43.929% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -37.731% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -193.758% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 67.234% |
| ContraFect Corporation | -56.88 Million USD | 95.191% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 39.931% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -95.151% |
| IMV Inc. | -38.67 Million USD | 92.925% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 0.539% |
| MultiCell Technologies, Inc. | -722.81 USD | -378422.71% |
| ONE Bio Corp. | 13.68 Million USD | 119.998% |
| Accustem Sciences Inc. | -3.74 Million USD | 26.97% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 95.362% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -466.387% |
| Q BioMed Inc. | -3.44 Million USD | 20.595% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 177.288% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -4.129% |
| Biomind Labs Inc. | -1 Million USD | -170.998% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 95.023% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 5.696% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 58.845% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -46.752% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -9034.615% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -41.57% |
| GB Sciences, Inc. | -1.42 Million USD | -92.607% |
| Alpha Cognition Inc. | -9.7 Million USD | 71.81% |
| HST Global, Inc. | -140.9 Thousand USD | -1841.706% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -143.22% |
| Halberd Corporation | -75.05 Thousand USD | -3545.57% |
| Enzolytics Inc. | -2.14 Million USD | -27.327% |
| Agentix Corp. | -1.37 Million USD | -99.452% |
| Resverlogix Corp. | -12.74 Million USD | 78.539% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 13.644% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.356% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -162.069% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 6.284% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -73.235% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 19.647% |
| AVAX Technologies, Inc. | 6.69 Million USD | 140.879% |
| Zenith Capital Corp. | -8.94 Million USD | 69.406% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.342% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -15605.183% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -11.432% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1495.247% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -36.475% |
| Kadimastem Ltd | -3.04 Million USD | 10.007% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -178.034% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1407.563% |
| LadRx Corporation | -3.82 Million USD | 28.445% |
| Cell Source, Inc. | -4.32 Million USD | 36.745% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -298.282% |
| NovAccess Global Inc. | -2.46 Million USD | -10.915% |
| Affymax, Inc. | -15.04 Million USD | 81.816% |
| Itoco Inc. | -919.14 Thousand USD | -197.67% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 35.448% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -144.504% |
| Mobile Lads Corp. | -554.55 Thousand USD | -393.373% |
| CytoDyn Inc. | -18.05 Million USD | 84.849% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -10770.083% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1143.196% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -384.485% |
| SYBLEU INC | -149.18 Thousand USD | -1734.026% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -50.634% |
| International Stem Cell Corporation | -663 Thousand USD | -312.67% |
| Bioxytran, Inc. | -3.82 Million USD | 28.38% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -5097.568% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -13351.327% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 92.456% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -69.098% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -271.822% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 12.054% |
| Neutra Corp. | -229.48 Thousand USD | -1092.23% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 84.4% |
| PureTech Health plc | -146.19 Million USD | 98.129% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 87.269% |
| IXICO plc | -1.43 Million USD | -90.397% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 71.173% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.754% |
| CSL Limited | 3.81 Billion USD | 100.072% |
| Cellectis S.A. | -108.85 Million USD | 97.487% |